February 4, 2025

Rudy Tanzi – Alzheimer’s Updates and Developments; What’s New? (part 2)

Rudy Tanzi – Alzheimer’s Updates and Developments; What’s New? (part 2)

About This Episode

In this episode of BrainStorm host Meryl Comer continues her compelling interview with "Rockstar of Science" Dr. Rudy Tanzi, the pioneering Director of the Genetics and Aging Research Unit and Director of the McCance Center for Brain Health at Mass General Hospital. Dr. Tanzi unveils the secrets of brain health and Alzheimer's research. Exploring his innovative SHIELD framework, Dr. Tanzi offers practical strategies for cognitive wellness, from sleep and stress management to diet and lifelong learning.

The episode takes an innovative turn with AI-generated questions that probe the challenges of Alzheimer's research. Dr. Tanzi provides candid insights into prevention, early intervention, and the future of medical science, sharing an unexpectedly optimistic view of combating cognitive decline. Blending scientific expertise with actionable advice, this episode is a must-listen for anyone interested in brain health, aging, and medical innovation.

Support the show

BrainStorm Feed

100

2025 Year in Review and Predictions for 2026 with George Vradenburg

George Vradenburg, Chairman and Founder of UsAgainstAlzheimer's, sits down with host Meryl Comer for a comprehensive look at the state of Alzheimer's research, advocacy, and care in 2025.
LISTEN NOW
99

The Future of Alzheimer's Trials: AI, Biomarkers, and Remote Research – John Dwyer, CEO of The Global Alzheimer’s Platform (part 2)

In part 2 John Dwyer, CEO of the Global Alzheimer's Platform (GAP), and BrainStorm host Meryl Comer discuss transforming Alzheimer's research and clinical trials.
LISTEN NOW
98

The Future of Alzheimer's Trials: Bringing Cutting-Edge Research to Every Community - John Dwyer, CEO of The Global Alzheimer's Platform

John Dwyer, CEO of the Global Alzheimer's Platform (GAP), highlights GAP's innovations in improving the participant experience through streamlining visits, personalized feedback, and bringing mobile trials directly to small communities.
LISTEN NOW